Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
In silico methods for metabolomic and toxicity prediction of zearalenone, α-zearalenone and β-zearalenone

Fojan Agahi, Cristina Juan *, Guillermina Font, Ana Juan-García

Laboratory of Food Chemistry and Toxicology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100, Burjassot, Valencia, Spain

ARTICLE INFO

Keywords:
Zearalenone
Metabolomics Prediction
SwissADME
PASS online
MetaTox
In silico

ABSTRACT

Zearalenone (ZEA), α-zearalenol (α-ZEL) and β-zearalenol (β-ZEL) (ZEA’s metabolites) are co/present in cereals, fruits or their products. All three with other compounds, constitute a cocktail-mixture that consumers (and also animals) are exposed and never entirely evaluated, nor in vitro nor in vivo. Effect of ZEA has been correlated to endocrine disruptor alterations as well as its metabolites (α-ZEL and β-ZEL); however, toxic effects associated to metabolites generated once ingested are unknown and difficult to study. The present study defines the metabolomics profile of all three mycotoxins (ZEA, α-ZEL and β-ZEL) and explores the prediction of their toxic effects proposing an in silico workflow by using three programs of predictions: MetaTox, SwissADME and PASS online. Metabolomic profile was also defined and toxic effect evaluated for all metabolite products from Phase I and II reaction (a total of 15 compounds). Results revealed that products describing metabolomics profile were: from O-glucuronidation (1z and 2z for ZEA and 1 ab, 2 ab and 3 ab for ZEA’s metabolites), S-sulfation (3z and 4z for ZEA and 4 ab, 5 ab and 6 ab for ZEA’s metabolites) and hydrolysis (5z and 7 ab for ZEA’s metabolites, respectively). Lipinsky’s rule-of-five was followed by all compounds except those coming from O-glucuronidation (HBA >10). Metabolite products had better properties to reach blood brain barrier than initial mycotoxins. According to Pa values (probability of activation) order of toxic effects studied was carcinogenicity > nephrotoxic > hepatotoxic > endocrine disruptor > mutagenic (AMES TEST) > genotoxic. Prediction of inhibition, induction and substrate function on different isoforms of Cytochrome P450 (CYP1A1, CYP1A2, CYP2C9 and CYP3A4) varied for each compounds analyzed; similarly, for activation of caspases 3 and 8. Relying to our findings, the metabolomics profile of ZEA, α-ZEL and β-ZEL analyzed by in silico programs predicts alteration of systems/pathways/mechanisms that ends up causing several toxic effects, giving an excellent sight and direct studies before starting in vitro or in vivo assays contributing to 3Rs principle; however, confirmation can be only demonstrated by performing those assays.

1. Introduction

Mycotoxins are low-molecular-weight toxic compounds synthetized by different types of molds belonging mainly to the genera Aspergillus, Penicillium, Fusarium and Alternaria (Berthiller et al., 2015; Juan et al., 2020; Pascari et al., 2019). Effects associated are diverse according to the chemical structure which provides a great variety in ADME/T characteristics (absorption, distribution, metabolism, and excretion/toxicity) and still to elucidate for most of them.

Zearalenone (ZEA) is a Fusarium mycotoxin of primary concern. It is commonly found in cereals like barley, sorghum, oats, wheat, millet, and rice (Juan et al., 2017a, 2017b; Stanciu et al., 2017; Bakker et al., 2018; Oueslati et al., 2020). When ingested and metabolized, two major metabolites, α-zearalenol (α-ZEL) and β-zearalenol (β-ZEL), can be found in various tissues; nonetheless, their presence is starting to be commonly found in food and feed as natural contaminants (EFSA et al., 2011, 2017). Once ingested by the consumer, further metabolite products from all three mycotoxins (ZEA, α-ZEL and β-ZEL) can be generated by Phase I and II reactions, although their effect is unknown. Studies of these compounds contribute to metabolomics profile for following the compound transformation (metabolic changes) whose identification and quantification will help to elucidate the complete toxic effects. It can help to understand global metabolic disturbances.

Effects associated to ZEA, α-ZEL and β-ZEL have been studied in vitro and in vivo and estrogenic effect, oxidative stress, cytotoxicity, DNA damage, among others have been reported (Eze et al., 2019; Frizzell...
Prediction of the entire potential effects of three mycotoxins (zearalenone metabolites, here it is presented an in silico approach that reveals biological activities of compounds, their metabolite likeness and structural-biotransformation reactions in predicting metabolites for complex mixtures) (Agahi et al., 2020; Juan-García et al., 2020; et al., 2011; Agahi et al., 2020; Juan-García et al., 2020). On the other hand, the entire implication of these compounds in producing toxic effects are unknown, same as with its metabolite products originated in Phase I and II reactions. So that, there are many indirect or side effects associated yet not studied and their involvement in pathways, cascade or routes still need to be discovered. Nowadays, the development of computational and informatics programs facilitates to predict experimental approaches in toxicology which need to be confirmed with further assays. These systems use chemical structures, parameters and descriptors which by comparison with other studied compounds, can give as a result empirical knowledge of their effect to prevent against exposure or even to promote the development of therapeutics to avoid or decrease toxic effects, concerning drugs.

Combination of compounds is a routine practice in medicine for palliative diseases achieving successful results. Previous to this practice it is necessary to evaluate the potential effects that this might cause. For toxic compounds there have been developed several mathematical methods implemented in informatics programs for assessing the effect of compounds’ combination and effects contributing to computational toxicology: Choy and Talalay by using isobolograms, Simple Addition of Effect, Factorial Analysis of Variance by using simple 2-way ANOVA, Bliss Independence Criterion, Loewe’s Additivity Law, Highest Single Agent (HSA) Model (Gaddums non-interaction), etc. (Kifer et al., 2020).

For mycotoxins’ mixture assessment, Choy and Talalay method has been widely used in predicting potential effects (synergism, addition and antagonism) (Juan-García et al., 2016, 2019a, 2019b; Agahi et al., 2020) even with strong differences in chemical structures as well as in the variety of fungi spp. producer.

The global research scenario for new therapies and development of new drugs for common diseases, or as it is happening nowadays in the global world pandemic SARS-COV-19 for health side-effects, the use of virtual screening techniques for helping in the discovery of new strategies and without using or avoiding long-term biological assays, is a good alternative. All these strategies end-up in exploring profile of effects by application of computer programs. One of this alternative programs is PASS online (Prediction of Activity Spectra for Substances) an in silico approach that reveals biological activities of compounds, their mechanisms of action and connected side-effects (Lagunin et al., 2000). The available PASS online version predicts over 4000 kinds of biological activity, including pharmacological effects, mechanisms of action, toxic and adverse effects, interaction with metabolic enzymes and transporters, influence on gene expression, etc. as described on its web page (http://www.swissadme.ch/index.php) (Daina et al., 2017; Cheng et al., 2012; Yang et al., 2018) and following the Lipinski’s rule of five (ROS) (see section 2.2, below) and ii)SwissSimilarity which provides an identification number HMBDB (Human Metabolome Database version 4.0, https://hmdb.ca/) with a score associated (Zoete et al., 2016). Afterward, all compounds were predicted as active compounds or inactive compounds according to probability of activation values (Pα) and probability of inactivation values (Pβ), respectively; as well as their biological activities through PASS online software (http://www.pharmaexpert.ru/passonline/info.php) (Workflow 1). Lastly, potential toxic effects were predicted for Pa > Pβ with PASS online software.

2.2. In silico software: MetaTox, SwissADME and PASS online

Three in silico softwares available online for studying prediction of toxicity and biological activities were used: MetaTox, SwissADME and PASS online.

MetaTox is a software based in generating metabolites and calculating probability of their formation where metabolism pathway generation is integrated with the prediction of acute toxicity. Metabolomics’ profile is predicted by the formation from nine classes of reactions (aliphatic and aromatic hydroxylation, N and O-glucuronidation, N-, S- and C-oxidation, and N- and O-dealkylation) that are catalyzed by five human isoforms of cytochromes P450s (1A2, 2C19, 2C9, 2D6, 3A4) and by human UDP glucuronosyltransferase without differentiation into isoforms. The calculation of probability for generated metabolites is based on analyses of "structure-biotransformation reactions" and "structure-modified atoms" relationships using a Bayesian approach (Rudik et al., 2017).

SwissADME is a web tool that enables to predict the computation of key physicochemical properties, pharmacokinetics, mycotoxin-likeness and medicinal chemistryfriendliness (for one or multiple molecules), (Daina et al., 2017; Cheng et al., 2012; Yang et al., 2018). This predictive in silico model shows statistical significance, predictive power, intuitive interpretation, and straight forward translation to molecular design. This program uses Lipinski’s rule-of-five (ROS) for the lead compounds. The compounds were then filtered through that rule (ROS) to predict their mycotoxins likeness. Lipinski’s descriptors evaluate the molecular properties for compound pharmacokinetics in the human body, especially for oral absorption. The rule states molecules to have: molecular weight (MW) ≤ 500, number of hydrogen bond donors (HBD) ≤ 5, number of hydrogen bond acceptors (HBA) ≤ 10, clogP ≤ 5 and number of rotatable bounds (n-ROTB) ≤ 10. Molar reactivity in the range of 40–130 and topological polar surface area (TPSA) were also considered. Targets of p-glycoprotein (P-gp) efflux and isoforms of cytochrome P450 that metabolize the majority of toxic compounds (CYP3A4, CYP2C9, CYP2C19, CYP1A1 and CYP1A2) were investigated.

The biological prediction of activity spectra for mycotoxins and...
metabolite products were obtained by PASS online (available in www.pharmaexpert.ru/passonline) (Lagunin et al., 2000). This software was used to evaluate the general biological potential of all compounds and provided simultaneous prediction of several types of biological activity based on their chemical structure. It also estimated the predicted activity spectrum of mycotoxins as probable activity (Pa, probability to be active) and probable inactivity (Pi, probability to be inactive). Both probabilities, Pa and Pi values, vary from 0.000 to 1.000; nevertheless, 

**Workflow 1.** Procedure followed to predict the toxic effect of mycotoxins and its metabolite products by using different in silico programs.
values are expressed as percentage of probability (%).

Among all toxic effects for all three mycotoxins and products of Phase I and II reactions provided from PASS, prediction was evaluated for: carcinogenesis, endocrine disruption, nephrotoxicity, mutagenicity (with and without AMES test), genotoxicity and hepatotoxicity. Biological activities prediction inhibiting, inducing or as substrate was evaluated for different isoforms of Cytochrome P450 and caspases 3 and 8. All predictions of probabilities were expressed as percentage of probability (%).

3. Results

3.1. Meta-Tox for predicting metabolite products: describing the metabolomics profile

Metabolite prediction included in MetaTox uses dictionaries of biotransformation based on preliminary prediction of possible classes of biotransformation describing also the metabolomics profile of the compounds. Mycotoxins’ canonical SMILE structure were used to predict metabolite products in MetaTox. Fig. 1 collects chemical structure of mycotoxins and metabolite products predicted by MetaTox (five from ZEA (from 1z to 5z) and 7 for each ZEA’s metabolite (from 1 ab to 7 ab)). Metabolite products predicted for ZEA were from: reaction of O-glucuronidation (metabolites 1z and 2z), reaction of S-sulfation (metabolites 3z and 4z) corresponding to Phase II products and one from reaction of hydrolysis (5z) corresponding to Phase I products. For α-ZEL and β-ZEL, products were equal for each one with a total of seven products for each isoform and corresponding to same reactions as ZEA: O-glucuronidation (metabolites: 1 ab, 2 ab and 3 ab), S-sulfation (metabolites: 4 ab, 5 ab and 6 ab) and hydrolysis (metabolite 7 ab) reactions. A total of 12 compounds were proposed as predicted metabolites products form Phase I and II reactions.

3.2. SwissADME for physicochemical descriptors of zearalenone, α-zearalenol, β-zearalenol and phase I and II metabolite products

Target of mycotoxins in organs and systems are wide and unknown for most of them; however, they are able to activate several routes or pathways. ZEA, α-ZEL and β-ZEL were analyzed through SwissADME online server for molecular properties to validate them as potential inducers/activators of toxic mechanisms. All three mycotoxins were filtered through Lipinski’s RO5 to predict their mycotoxin likeliness (Table 1). All three mycotoxins and metabolite products were studied and only metabolites coming from O-glucuronidation of ZEA (metabolites 1z and 2z) or α-ZEL and β-ZEL (metabolites 1 ab, 2 ab and 3 ab) violated Lipinski’s rule because of HBA (hydrogen bond acceptor) (Table 1). It is also reported the human metabolome database identification number (HMDB ID) and the score of similarity predicted provided from SwissSimilarity. All compounds had one or more HMDB ID with score >50% (Table 1). To notice that values were the same for metabolite products coming from the same metabolization reaction.

Table 2

|                      | ZEA              | α-ZEL and β-ZEL |
|----------------------|------------------|-----------------|
| Absorption & Distribution | 28.22            | 31.47           |
| BBB                  | 97.61            | 97.50           |
| P-gp substrate       | 85.50            | 84.12           |
| Caco-2 permeability  | 48.84            | 59.94           |
| LogP (cm/s)          | -5.67            | -5.39           |
| Metabolism           |                  |                 |
| CYP450 2C9 substrate | 57.95            | 60.44           |
| CYP450 2D6 substrate | 86.69            | 83.54           |
| CYP450 3A4 substrate | 55.40            | 57.08           |
| CYP450 1A2 inhibitor | 68.95            | 76.60           |
| CYP450 2C9 inhibitor | 84.90            | 89.37           |
| CYP450 2D6 inhibitor | 91.60            | 90.07           |
| CYP450 2C19 inhibitor| 75.95            | 72.46           |
| CYP450 3A4 inhibitor | 79.60            | 76.82           |
| Toxicity             |                  |                 |
| Ames toxicity        | 90.0             | 85.00           |
| Carcinogens          | 90.0             | 66.04           |
| Rat acute toxicity   | 1.88             | 1.94            |

BBB: blood-brain barrier; HIA: human gastrointestinal absorption; P-gp: P-glycoprotein.

Table 1

|                  | ZEA               | α-ZEL and β-ZEL |
|------------------|-------------------|-----------------|
| HMDB ID          | MW (≤500)         | HBD (≤5)        | HBA (≤10) | cLogP (≤5) | MR (≤10) | n-ROTB (≤10) | TPSA |
| ZEA              | 31,752 (99.6%)    | 318.37          | 2         | 5          | 3.58     | 88.40       | 0    | 83.83        |
| O-Glucuronidation|                  |                 |           |            |          |             |      |              |
| Metabolite 1z*   | 34,753 (74.1%)    | 494.49          | 5         | 11*        | 1.14     | 121.13      | 3    | 180.05       |
| Metabolite 2z*   | 60,634 (84.3%)    |                 |           |            |          |             |      |              |
| O-Sulfation      | 33,623 (99.6%)    | 398.43          | 2         | 8          | 3.06     | 98.60       | 2    | 135.58       |
| Metabolite 3z    | 31,752 (87.6%)    |                 |           |            |          |             |      |              |
| Metabolite 4z    | 31,752 (87.6%)    |                 |           |            |          |             |      |              |
| Hydrolysis       |                  |                 |           |            |          |             |      |              |
| Metabolite 5z    | 31,752 (52.4%)    | 336.38          | 4         | 6          | 3.10     | 92.16       | 10   | 115.06       |
| α-ZEL and β-ZEL  |                  |                 |           |            |          |             |      |              |
| O-Glucuronidation|                  |                 |           |            |          |             |      |              |
| Metabolite 1 ab* | 34,753 (86.8%)    | 496.51          | 6         | 11*        | 0.94     | 122.09      | 3    | 183.21       |
| Metabolite 2 ab* | 60,634 (75.6%)    |                 |           |            |          |             |      |              |
| Metabolite 3 ab* | 31,752 (53.9%)    |                 |           |            |          |             |      |              |
| O-Sulfation      | 33,623 (91.5%)    | 400.45          | 3         | 8          | 2.85     | 99.56       | 2    | 138.74       |
| Metabolite 4 ab  | 31,752 (90.4%)    |                 |           |            |          |             |      |              |
| Metabolite 5 ab  | 41,838 (91.1%)    |                 |           |            |          |             |      |              |
| Metabolite 6 ab  | 31,752 (99.6%)    |                 |           |            |          |             |      |              |
| Hydrolysis       | 41,824 (50.6%)    | 338.40          | 5         | 6          | 2.89     | 93.12       | 10   | 118.22       |

HMDB ID = Human Metabolome Database Identification; MW = Molecular weight; g/mol (acceptable range: ≤500); HBD = Hydrogen bond donor (acceptable range: ≤10); HBA = Hydrogen bond acceptor (acceptable range: ≤10); cLogP = High lipophilicity (expressed as LogP, acceptable range: ≤5); MR = Molar refractivity (acceptable range: 40–130); n-ROTB: number of rotatable bounds; TPSA = Topological polar surface area; Å². * Denotes violation of Lipinski’s RO5.
from 68.95% (isoform 1A2) to 91.60% (isoform 2D6). For toxins. Probability of ZEA as substrate in CYP450 went from 55.40% and P-glycoprotein substrateported for all three mycotoxins (HIAβ-ZEL, as substrates of CYP450 probability went from 60.44% (isoform 1A2) to 90.07% (isoform 2D6) (Table 2). The results indicate moderate to high absorption by the gastrointestinal tract, but unlikely to penetrate into the brain on its current form unless metabolized (Table 3). Distribution (P-gp substrate) was favored with probability >84%. For metabolism prediction, several cytochrome P450 (CYP450) isoenzymes were evaluated showing similar pattern for all three mycotoxins. Probability of ZEA as substrate in CYP450 went from 57.71% to 92.29% (metabolites 1z and 2z) for α-ZEL and β-ZEL. In genotoxicity (88.4%) (Fig. 2A). Among toxic effects studied, for all metabolite products (5 from ZEA and 7 from β-ZEL), carcinogenicity reported the highest probability for all three mycotoxins followed by nephrotoxic > hepatotoxic > endocrine disruptor > mutagenic (AMES TEST) > genotoxic (Fig. 2B). Nonetheless, metabolite products from ZEA mycotoxin had the broadest range of probability in all toxic effects studied. Details of toxic effects per metabolite product from Phase I and II reactions are reported in Supplementary 1. Regarding the carcinogenicity effect predictions in rat and mouse (male and female), and the IARC classification is reported in Supplementary 2.

### 3.3. Prediction of toxic effects by PASS online

Mycotoxins and products from metabolomics profile were studied by PASS online (Workflow 1). To validate them as suitable inducers/activator candidates, PASS online server was used which predicts possible effects of a compound based on its structural information. This tool compares more than 300 effects and biochemical mechanisms of compounds and gives the probability of activity (Pa) and inactivity (Pi) (Hassan et al., 2019).

Fig. 2 shows the probability for seven different toxic effects: carcinogenicity, endocrine disruptor, nephrotoxic, mutagenicity (and AMES test), genotoxicity and hepatotoxicity. It can be observed that ZEA had the highest probability in reporting carcinogenicity (78.2%); while α-ZEL and β-ZEL, carcinogenicity reported the highest probability for all three mycotoxins followed by nephrotoxic > hepatotoxic > endocrine disruptor > mutagenic (AMES TEST) > genotoxic (Fig. 2B). Nonetheless, metabolite products from ZEA mycotoxin had the broadest range of probability in all toxic effects studied. Details of toxic effects per metabolite product from Phase I and II reactions are reported in Supplementary 1. Regarding the carcinogenicity effect predictions in rat and mouse (male and female), and the IARC classification is reported in Supplementary 2.

### 3.4. Prediction of biological activities by PASS online

Biological activities predicted by PASS online are reported in Figs. 3 and 4. It has been divided in one hand the most common isofoms of cytochrome P450 involved in metabolizing toxic compounds (Fig. 3); and in the other hand, cysteine proteases enzymes which are primary effectors in cell death: caspase 3 and caspase 8 (Fig. 4).
3.4.1. Cytochrome P450

Prediction effects on isoforms of Cytochrome P450 (CYP1A1, CYP1A2, CYP2C9 and CYP3A4) are reported in Fig. 3 for all three mycotoxins and compounds defined in the metabolomics profile (from Phase I and II reactions). Effects are reported for each compounds acting as substrate, inducer or inhibitor. For all CYP450 isoforms all three mycotoxins reported effect as substrates, inducers and inhibitors; however, α-ZEL and β-ZEL reported higher probability prediction than ZEA in all of them independently of its mode of action (Fig. 3).

In detail, for isoform CYP1A1, all compounds had effects on it (Fig. 3A). Metabolite products coming from α-ZEL and β-ZEL had slightly higher probability prediction as substrate (>37%) than ZEA (>35%) for all O-glucuronidation, S-sulfation and hydrolysis products; as inducers, only metabolite products coming from O-glucuronidation reported this prediction effects. Finally, as inhibitor, only metabolite 5z from hydrolysis of ZEA and 6 ab from S-sulfation of α-ZEL and β-ZEL presented such prediction both in 30% (Fig. 3A).

For isoform CYP1A2, ZEA metabolite products had effects on it as substrate, except those coming from S-sulfation; and products of S-sulfation from α-ZEL and β-ZEL had no-effect (Fig. 3B). As inducers of this isoform (CYP1A2), only metabolite products of S-sulfation from ZEA (3z and 4z) were predicted in 16%. As inhibitor none of the compounds reported prediction in this direction (Fig. 3B).

For isoform CYP2C9, ZEA, α-ZEL and β-ZEL were predicted as substrate; while only ZEA as inducer and α-ZEL and β-ZEL as inhibitor (Fig. 3C). For metabolite products coming from O-glucuronidation of these mycotoxins all were predicted as i) substrate: 54% for those coming from ZEA and >60% for those coming from α-ZEL and β-ZEL; and as ii) inducers: >38% for all those coming from ZEA and from α-ZEL and β-ZEL. Metabolite product of hydrolysis coming from ZEA (5z) was predicted only as inducer (26%); while that coming from α-ZEL and β-ZEL (7 ab) was predicted as substrate (22%), inhibitor (23%) and inducer (26%). However, no-effect was predicted for S-sulfation compounds (neither as substrate, inhibitor or inducer).

Finally, ZEA, α-ZEL and β-ZEL were predicted as substrate and inducers with probabilities >60% for isoform CYP3A4 (Fig. 3D). All metabolite products from ZEA of O-glucuronidation and S-sulfation were predicted as substrate ranging from 32% (2z) to 61% (4z); and inducers ranging from 57% (4z) to 80% (1z). No effect was predicted for its hydrolysis product (5z). Similar prediction effect was observed for metabolite products from α-ZEL and β-ZEL as substrates ranging from 38% (1 ab) to 81% (5 ab) and as inducers ranging from 58% (6 ab) to 81% (3 ab). The hydrolysis product 7 ab, was only predicted as substrate (35%) (Fig. 3D).

3.4.2. Caspases 3 and 8

Caspases are involved in cascade activation of cell death, occurring either naturally or by exposure to toxic compounds. Prediction for caspases 3 and 8 activation (stimulation) is reported in Fig. 4 A and B, respectively of all 15 compounds. Prediction of activation of both caspases, 3 and 8, was higher for α-ZEL and β-ZEL (86% and 49% for caspase 3 and 8, respectively) than for ZEA (73% and 43% for caspase 3 and 8, respectively).

Caspase 3 was activated for all compounds studied and for metabolite predicted from α-ZEL and β-ZEL probability was higher than those from ZEA (Fig. 4A). Metabolite products of i) O-glucuronidation from α-ZEL and β-ZEL reported caspase activation >80% while those from ZEA <77%; ii) S-sulfation from α-ZEL and β-ZEL reported caspase...
activation >36% while those from ZEA <30% and iii) hydrolysis from \( \alpha \)-ZEL and \( \beta \)-ZEL reported caspase activation 33% while those from ZEA 35% (Fig. 4A).

For caspase 8, ZEA metabolite products reported prediction of activation only from those coming from O-glucuronidation and hydrolysis, from 56% to 29%, respectively (Fig. 4B); while those metabolites products coming from \( \alpha \)-ZEL and \( \beta \)-ZEL reported activation of caspases from 51% (1ab) to 60% (3ab) for O-glucuronidation products, from 25% (6ab) to 27% (4ab) for S-sulfation products and 34% (7ab) for the hydrolysis product (Fig. 4B).

### 4. Discussion

The present study explores the prediction of toxicity of three mycotoxins (ZEA, \( \alpha \)-ZEL and \( \beta \)-ZEL) and products defining its metabolomics profile by proposing an in silico workflow and by using three software of computational toxicology: MetaTox, SwissADME and PASS online. All three mycotoxins are well-known to be copresent in food and feed not following good manufacture/agricultural practices, generating a public health concern as well as agricultural economic losses. Its effect as endocrine disruptor has been widely reported although the implications of its metabolite products regarding that toxic effects (or others) are unknown.

The workflow proposed, uses MetaTox to obtain the metabolite products formed during Phase I and II reactions, contributing to describe the metabolomics profile (Rudik et al., 2017); SwissADME (Daina et al., 2017) here it has been used for assessing the ADMET processes suffered by three mycotoxins (ZEA, \( \alpha \)-ZEL and \( \beta \)-ZEL) and its metabolites products (1z-5z for ZEA and 1ab-7ab for \( \alpha \)-ZEL and \( \beta \)-ZEL); and PASS online, predicted the toxic effect of activation and the biological activities with probability values (Pa, probability of activation). Different parameters are used for each software program which help in predictions, but as it occurs with in vitro or in vivo studies, they must be prudently assessed (Workflow 1).

Metabolites products predicted through MetaTox for the mycotoxins studied came from two Phase II reactions: O-glucuronidation and S-sulfation. Both are detoxication reactions of first line facilitating excretion. ZEA was predicted to generate two metabolites for each type of reaction (from 1z to 4z); while for \( \alpha \)-ZEL and \( \beta \)-ZEL three metabolites (from 1ab to 6ab) (Fig. 1 and Table 1). For Phase I reaction, only hydrolysis reaction was predicted to take place from ZEA, \( \alpha \)-ZEL and \( \beta \)-ZEL, generating only one metabolite product, 7z and 7ab for ZEA and ZEA’s metabolites, respectively. In summary a total of 12 compounds defined the metabolomic profile of ZEA, \( \alpha \)-ZEL and \( \beta \)-ZEL (Fig. 1 and Table 1).

Coinciding with other studies, these reactions take place and generate these compounds; however, their effects are unknown; in fact, the use of these metabolite products as biomarkers have been found in the literature in biomonitoring studies (Lorenz et al., 2019; Follmann et al., 2016; Shephard et al., 2013; Wallin et al., 2015; Gerdig et al., 2015) or directly detected in food and aromatic plants as masked mycotoxins (Berthiller et al., 2006, 2009; Mannani et al., 2019). However, an analysis of in silico prediction of toxic effects defined by the metabolomics profile is here the first time reported. EFSA has dealt in assessing the risk of ZEA, \( \alpha \)-ZEL and \( \beta \)-ZEL and has indicated that metabolites...
products coming from them (also reported as modified forms) might have effects (oestrogenic effect, genotoxicity, endocrine receptor, …) (EFSA, 2011 and 2014) and contribute to the exposure evaluation but the uncertainty exists as there is a lack of data which entails difficulties in defining its toxic effects (EFSA et al., 2014, 2016, 2017). Not to mention the gap in effects of its mixtures or with other mycotoxins or contaminants.

In silico analysis show that ZEA, α-ZEL and β-ZEL are poorly achieving the BBB, have good distribution and are highly favored to be absorbed gastrointestinal (Table 2). The interesting point noticed with the analysis of metabolites product of these mycotoxins, obtained from O-glucuronidation, S-sulfation and hydrolysis reactions, is that these properties change inversely, especially for achieving the BBB (see values from Tables 2 and 3) from low values to high values. There are studies coinciding and others opposite to the results predicted in here when compared with those reported by in vivo and in vitro studies. For all three mycotoxins it has been reported a good gastrointestinal absorption (rapid and extensive) as well as the formation of metabolites from hydrolysis, sulfation and glucuronidation (Biehl et al., 1993; Frizzell et al., 2015; Pfeiffer et al., 2011; Plasencia et al., 1991); in fact, several strategies and recommendations have been also considered for the entire risk assessment (EFSA 2017; Lorenz et al., 2019). Optimal gastrointestinal absorption predicted by Lipinsky RO5 is reported in Table 1 for the metabolomics profile. It also indicates that the probability of one compound to be absorbed orally is directly related to the ADMET and toxic effects. Only metabolites coming from O-glucuronidation were not following the Lipinsky’s RO5 (HBA >10), because of not passing the gastrointestinal barrier; however, mycotoxins, and metabolites from S-sulfation and hydrolysis reactions did which indicates their good distribution.

Toxic effects associated to compounds from metabolomics profile and mycotoxins seem to contribute one to another. Related to this, EFSA has indicated to assume the toxic effects of one compound as the sum of all metabolites coming from that compound (EFSA, 2011; Lorenz et al., 2019). Nonetheless, it is possible to analyze individual predictions in silico. The most common effect associated to ZEA as well as ZEA’s metabolites is as endocrine disruptors with a ranking of oestrogenic potency (EFSA 2011). Besides this common and demonstrated toxic effect through in vitro and in vivo assays (EFSA 2017; Eze et al., 2019), other effects according to several parameters can be predicted (Fig. 2A) as well as for its metabolite products (Fig. 2B). According to the analysis of main effects predicted in silico for ZEA, α-ZEL, β-ZEL and its metabolite product defining the metabolomic profile, carcinogenicity is the toxic effect predicted with high probability; however, IARC has classified ZEA (since 1993) as Group 3 (not classifiable as to their carcinogenicity to humans) based on inadequate evidence in humans and limited evidence in experimental animals (IARC 1993); to mention different behave in mice and mouse with limited evidence reported. This explains the prediction described in Fig. 2, which although carcinogenicity indicates high probability (80–90%), the evidence is not coinciding with assays carried out for evaluating such effect. This is not happening with other effects reported in Fig. 2 which coincide with studies carried out either in vivo or in vitro (especially for ZEA as it is the most studied): mutagenicity (Abbès et al., 2007; Ben Salah-Abbès et al., 2009); nephotoxic in rats (Becchi et al., 1982), genotoxic (Ouanes et al., 2003, 2005; El-Makawy et al., 2001). As mentioned before the prediction needs to be confirmed with further assays without forgetting that it is giving a valuable indication to start from.

Cytochrome P450 (CYP450) is an enzymatic complex important as mechanism of defense by the organism when in contact with contaminants. Its main function is to metabolize the majority of toxic compounds through Phase I reactions. It is constituted by several isozymes to highlight the following as the most implicated in defense: CYP3A4, CYP2C9, CYP2C19, CYP1A1 and CYP1A2 (SwissADME). Expression of different isozymes occurs by exposure to contaminants as mycotoxins; which can act as inhibitors, inducers or substrates of this enzymatic complex. Results reported in Fig. 3 reveal that the highest predictions effects were for CYP3A4 (40–80%) (Fig. 3D). When analyzing the action of mycotoxins, all three act as substrate, inducers and inhibitors ranging from 60% to 90%, from 21% to 38% and from 23% to 32%, respectively for isozymes CYP1A1 and CYP1A2 (Fig. 3); while as substrate (62–71%) and inducers (89%) for CYP3A4. Finally, for isozyme CYP2C9, ZEA act as substrate and inducer and, α-ZEL and β-ZEL as substrate and inhibitor (Fig. 3). For metabolite products, probabilities of action were marked for isoform CYP3A4. This isoform jointly CYP1A2 have been reported to play an important role in metabolism of ZEA in humans (Pfeiffer et al., 2009); while jointly with CYP2C8 denotes a high activation hydroxylation of ZEA (Bravin et al., 2009). In summary, different isoforms CYP seem to contribute in the metabolism of all 15 compounds according to in silico prediction which coincides with the studies performed in vitro (Pfeiffer et al., 2009; Bravin et al., 2009); and more specifically with the isoform CYP3A4 which has the highest values of probability (Fig. 3D).

Apoptotic cell death has been studied for ZEA in vitro revealing that activation of caspase 3 and 8 occurs (Banjerdpongchai et al., 2020; Gazzah et al., 2010; Othmen et al., 2008; Agahi et al., 2020 Zhu et al., 2012); as well as for α-ZEL and β-ZEL (Abid-Essefi et al., 2009). Nothing
is known for its metabolite products defined in the metabolomics profile. Both caspases, implicated in the cascade activation for apoptotic cell death, have been predicted in silico as reported in Fig. 4. Results for ZEA coincide with those reported in the literature in vitro denoting a major activation for caspase 3 than caspase-8 (Barjerdpongchai et al., 2010). Among that, similar tendency was observed for all the other 14 compounds studied; and while O-glucuronidates present highest prediction of activation for both caspase-3 and 8 and all compounds, S-sulfation products from ZEA (3z and 4z) do not contribute to activation of cell death through caspase-8 (Fig. 4B). The prediction presented in this work in cell death and the in vitro confirmation reported for ZEA, α-ZEL and β-ZEL reveal that the apoptosis pathway of cell death is contributed by its metabolite products, which are generated during its detoxification by Phase I and II reactions.

5. Conclusions

In conclusion, the results obtained in the present study indicate that toxicity of ZEA, α-ZEL and β-ZEL mycotoxins and their metabolomics' profile can be predicted in silico. MetaTox was able to predict a total of 12 metabolites defining the metabolomics profile of each mycotoxin studied (5 from ZEA and 7 from α-ZEL and β-ZEL). SwissADME permitted to analyze each compound by its physicochemical properties and predict the behavior of each one according to its absorption, distribution, metabolism and toxicity. Among that it was possible to assign a HMDB ID according to a score of similarity. Lastly, PASS online provided an entire prediction of all compounds based on its structural information reported in Pa values. The results indicate moderate to high absorption by the gastrointestinal tract, but unlikely to penetrate into the brain on its current form unless metabolized. Slightly better properties to reach blood brain barrier than initial mycotoxins were observed. Toxic effects associated for all compounds revealed that carcinogenicity reported the highest probability for all three mycotoxins followed by nephrotoxic > hepatotoxic > endocrine disruptor > mutagenic (AMES TEST) > genotoxic. Prediction of inhibition, induction and substrate function on different isoforms of Cytochrome P450 varied for each compounds analyzed; similarly, for activation of caspases 3 and 8.

The metabolomics profile of ZEA, α-ZEL and β-ZEL analyzed by in silico programs (MetaTox, SwissADME and PASS online) predicts alteration of systems/pathways/mechanisms that ends up causing several toxic effects, giving an excellent sight and direct studies before starting in vitro or in vivo assays contributing to 3Rs principle by a reduction of animal testing. This innovative proposal in the field of computer toxicology helps (and opens a new window) to investigate the chemical risk assessment, a topic of great interest amongst researchers and safety authorities; nonetheless, it is necessary to continue developing and performing assays that confirm the predictions estimated to achieve solidest conclusions.

Source of funding

This research was supported by the Spanish Ministry of Science and Innovation PID2019-108070RB-I00ALI and the Generalitat Valenciana GV2020/020, Generalitat Valenciana GVPMOMETE2018-126. Compliance with ethical standards.

CRediT authorship contribution statement

Fojan Agahi: Data curation, Investigation, Methodology, Visualization, Writing - original draft. Cristina Juan: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Visualization, Writing - original draft, Writing - review & editing. Ana Juan-Garcia: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Visualization, Writing - original draft, Writing - review & editing.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Authors would like to thank Spanish Ministry of Science and Innovation PID2019-108070RB-I00ALI, Generalitat Valenciana GV2020/020 and Generalitat Valenciana GVPMOMETE2018-126.

Appendix ASupplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.fct.2020.111818.

References

Abbas, S., Ouanez, Z., Salah-Abbes, J., Abdel-Wahhab, M.A., Oueslati, R., Bacha, H., 2007. Preventive role of aluminosilicate clay against induction of micronuclei and chromosome aberrations in bone marrow cells of Balb/c mice treated with zearalenone. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 631, 85–92.
Agahi, F., Álvarez-Ortega, N., Font, G., Juan-García, A., Juan, C., 2020. Oxidative stress, glutathione, and gene expression as key indicators in SH-SYSY cells exposed to zearalenone metabolites and beavericin. Toxicology Letters 334, 44–52.
Agahi, F., Font, G., Juan, C., Juan-García, A., 2020. Individual and combined effect of zearalenone derivatives and beavericin mycotoxins on SH-SYSY cells. Toxins 12, 212. https://doi.org/10.3390/toxins12040212.
Bakker, M.G., Brown, D.W., Kelly, A.C., Kim, H.S., Kurtzman, C.P., Mccormick, S.P., O’Donnell, K.L., Pruett, R.H., Vaughan, M.M., Ward, T.J., 2018. Fusarium mycotoxins: a trans-disciplinary overview. J. Indian Dent. Assoc. 40, 161–171.
Barjerdpongchai, R., Kongtawalert, P., Khantamat, O., Srisomsap, C., Chokchaisammankit, D., Subhaditanont, P., Svasti, J., 2010. Mitochondrial and endoplasmic reticulum stress pathways cooperate in zearalenone-induced apoptosis of human leukemic cells. J. Hematol. Oncol. 3, 50. http://www.jhoonline.org/content/3/1/50.
Becci, P.J., Yoon, K.A., Hess, F.G., Gallo, M.A., Parent, R.A., Stevens, K.R., Taylor, J.M., 1982. Long-term carcinogenicity and toxicity study of zearalenone in the rat. J. Appl. Toxicol. 2, 247–254.
Ben Salah-Abbes, J., Abbas, S., Abdel-Wahhab, M.A., Oueslati, R., 2009. Raphanus sativus extract protects against Zearalenone-induced reproductive toxicity, oxidative stress and mutagenic alterations in male Balb/c mice. Toxicon 53, 529–533.
Berthiller, F., Hameiter, C., Krenn, P., Schweiger, W., Ludwig, R., Adam, G., Kriska, R., Schuhmacher, R., 2009. Preparation and characterization of the conjugated Fusarium mycotoxins zearalenone-4β-D-glucopyranoside, alpha-zeareno1-40-beta-D-glucopyranoside and beta-zeareno1-40-beta-D-glucopyranoside by MS/MS and two-dimensional NMR. Food Additives & Contaminants. Part. A:Chemistry, Analysis, Control, Exposition & Risk Assessment 26, 207–213.
Berthiller, F., Werner, U., Solyov, M., Kriska, R., Hauser, M.T., Schuhmacher, R., 2006. Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) determination of phase II metabolites of the mycotoxin zearalenone in the model plant Arabidopsis thaliana. Food Addit. Contam. 23, 1194–1200.
Berthiller, F., Cresw, C., Dall’Anta, C., de Saeger, S., Haezeg, G., Karlowsky, P., Oswald, I.P., Seefelder, W., Speijers, G., Straka, J., 2013. Masked mycotoxins: a review. Mol. Nutr. Food Res. 57, 165–186.
Biele, M.L., Prelusky, D.B., Kozit, G.D., Hartin, K.E., Buck, W.B., Trenholm, H.L., 1993. Biliary excretion and enterogenous cycling of zearalenone in immature pigs. Toxicol. Appl. Pharmacol. 121, 152–159.
Bravin, F., Duca, R.C., Balaguer, P., Delafarge, M., 2009. In vitro cytochrome p450 formation of a monohydroxylated metabolite of zearalenone exhibiting estrogenic activities: possible occurrence of this metabolite in vivo. Int. J. Mol. Sci. 10, 1824–1837.
Cheng, F., Li, W., Zhou, Y., Shen, J., Wu, Z., Liu, G., Lee, P.W., Tang, Y., 2012. AdmetSAR: a comprehensive source and free tool for evaluating chemical ADMET properties. J. Chem. Inf. Model. 52, 3099–3109.
Daina, A., Michelini, O., Zorret, V., 2017. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717. https://doi.org/10.1038/srep42717.
EFSA European Food Safety Authority, 2011. Scientific Opinion on the risks for public health related to the presence of zearalenone in food. EFSA Journal 9 (6), 2197.
EFSA European Food Safety Authority, 2014. Scientific opinion on the risks for human and animal health related to the presence of modified forms of certain mycotoxins in food and feed. EFSA J 12, 2916. https://doi.org/10.2903/j.efsa.2014.3916.
El-Makawy, A., Hassane, M.S., Abd Alla, E.S., 2001. Genotoxic evaluation for the estrogenic mycotoxin zearalenone. Reprod. Nutr. Dev. 41, 79–89.

Eze, U.A., Huntriss, J., Routledge, M.N., Gong, Y.Y., Connolly, L., 2019. The effect of individual and mixtures of mycotoxins and persistent organochloride pesticides on oestrogen receptor transcriptional activation using in vitro reporter gene assays. Food Chem. Toxicol. 130, 68–78.

Follmann, W., Ali, N., Blaszewicz, M., Degen, G., 2016. Biomonitoring of mycotoxins in urine: pilot study in mill workers. J. Toxicol. Environ. Health. 79, 1015–1025.

Frizzell, C., Uhlig, S., Miles, C.O., Verhaegen, S., Elliott, C.T., Erksen, G.S., Sorlie, M., Ropstad, E., Connolly, L., 2015. Biotransformation of zearalenone and zearalenols to their major glucuronide metabolites reduces estrogenic activity. Toxicol. Vitro 29, 575–581.

Frizzell, C., Nollos, D., Verhaegen, S., Dahl, E., Erksen, G., Sorlie, M., Connolly, L., 2011. Endocrine disrupting effects of zearalenone, alpha- and beta-zearalenol at the level of nuclear receptor binding and steroidogenesis. Toxicol. Lett. 206 (2), 210–217.

Gazzah, A.C., Bennour, E.E., Bouaziz, C., Abid, S., Ladjimi, M., Bacha, H., 2010. Sequential evaluation of apoptosis induced by zearalenone in cultured hepatocarcinoma cells. Mycotoxin Res. 26, 187–197.

Gerding, J., Ali, N., Schwartzbord, J., Cramer, B., Brown, D.L., Humpf, H.U., 2015. A comparative study of the human urinary mycotoxin excretion patterns in Bangladesh, Germany, and Haiti using a rapid and sensitive LC-MS/MS approach. Mycotoxin Res. 31, 127–136.

Hasan, M.N., Bhuyan, N.M.M.A., Hoxun, M.K., 2019. In silicon molecular docking, PASS prediction, and ADME/T analysis for finding novel COX-2 inhibitor from Heliotropium indicum. J. Comp. Med. Res. 10, 142–154.

IARC (International Agency for Research on Cancer), 1993. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, 56. Some Naturally Occurring Substances: Heterocyclic Aromatic Amines and Mycotoxins, Lyon, pp. 39–444.

Juan, C., Maines, J., Font, G., Juan-García, A., 2017a. Determination of mycotoxins in fruit berry by-products using QuChERS extraction method. LWT - Food Sci. Technol. (Lebensmittel-Wissenschaft & Technologie) 86, 344–351.

Juan, C., Berrada, H., Maïes, J., Oueslati, S., 2017b. Multi-mycotoxin determination in barley and derived products from Tunisia and estimation of their dietary intake. Food Chem. Toxicol. 103, 148–156.

Juan, C., Mannai, A., Ben Salem, H., Oueslati, S., Berrada, H., Juan-García, A., Maïes, J., 2020. Mycotoxin presence in pre- and post-fermented silage from Tunisia. Arabian Food Sci. Technol. 26, 187–197.

Kifer, D., Jakši, D., Klari, M.S., 2020. Assessing the effect of mycotoxin combinations: which mathematical model is (the most) appropriate? Toxins 12, 153. https://doi.org/10.3390/toxins12030153.